Overview  >  Investor Relations  >  Why Invest
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of medicines and vaccines.
About Us
2026 Strategic Priorities
01

Maximize value of key transactions

02

Deliver on critical R&D milestones

03

Invest to maximize post-2028 growth

04

Scale AI across our business

Products

Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.

Browse All Products
Our Science

Pfizer’s transformative science fuels breakthroughs that change patients’ lives.

Powered by our robust, fully integrated R&D engine, Pfizer turns cutting-edge research into real-world treatments, solutions, and impact.

Our scientific innovation focuses on four priority therapeutic areas:


Explore Our Science
Oncology Icon

Oncology
Vaccines Icon

Vaccines
Internal Medicine Icon

Internal Medicine
Inflammation & Immunology Icon

Inflammation & Immunology
Pipeline Snapshot as of February 3, 2026
0
Phase 1
0
Phase 2
0
Phase 3
0
Registration
0
Total
Explore the Product Pipeline Key 2026 Catalysts
Learn More with Pfizer Pflash
Hear directly from Pfizer’s scientific leaders for a firsthand look into our pipeline, products, and people. Our Pfizer Pflash sessions offer an educational deep dive into the science powering Pfizer’s work.
Learn more
Our Financials
Pfizer is committed to enhancing long-term shareholder value through a balanced and disciplined capital allocation strategy. From our consistent dividend payout streak to our focus on sustainable growth, we remain dedicated to delivering long-term value to shareholders.
Quarterly Results Stock Information Dividend & Split History
2025 Milestones
Advancing Our Strategy
4
Key regulatory approvals1
1 U.S. Food and Drug Administration/European Medicines Agency.
8
Positive Phase 3 readouts
11
Pivotal study starts
Research & Development
102
projects in our pipeline (as of February 3, 2026)
Business Development
~$8.8B
invested in BD transactions
Global footprint
~75K
employees
Global Reach
~200
countries and territories where we supply our products
Returned
$9.8B
to shareholders through cash dividends in 2025
Revenue
$62.6B
in 2025
Invested
$10.4B
in internal R&D projects
>448M Patients reached
worldwide with our medicines and vaccines2
2 The Patients Reached metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by extemal sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and, in some cases, use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologles to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple petients towards total. Numbers include estimated patient counts from our Accord for a Healthier World program. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Patient Support Programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.